Since the lipid-lowering activity of PPARα agonists and insulin-sensitizing effect of PPARγ agonists are extremely well-established and have been widely exploited to improve dyslipidemia and T2DM [9,10,11,12], these aspects will be excluded from this review. Here, PPARA is linked to metabolic syndrome.